Icatibant Ratiopharm

Icatibant acetate, the active ingredient in Icatibant Ratiopharm, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid reduction of swelling and associated discomfort.

GNH USA supplies Icatibant Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable cold‑chain logistics for injectable products.

Icatibant Ratiopharm acts on the bradykinin pathway to manage hereditary angioedema.

- Acute hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during attacks. - Hereditary angioedema type I: reduces abdominal pain and facial edema associated with episodes. - Hereditary angioedema type II: improves airway patency by decreasing laryngeal swelling.

Icatibant Ratiopharm may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Angioedema of the face or throat: paradoxical swelling despite treatment. - Hypotension: sudden drop in blood pressure. - Severe injection‑site necrosis: tissue damage at the site. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant Ratiopharm, consider the following precautions to ensure safe administration.

- Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; unknown effects on the infant. - Renal impairment: monitor closely; dosage adjustment may be required. - Concomitant ACE inhibitor therapy: observe for enhanced bradykinin effects. - History of hypersensitivity: avoid if previous severe allergic reaction to icatibant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Ratiopharm can interact with other medicines that influence the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): can amplify bradykinin activity, leading to severe swelling.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate edema; monitor patient response. - Oral contraceptives: potential additive effect on vascular permeability. - Other bradykinin‑modulating agents: combined use may increase risk of adverse reactions.